[18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancer

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 15

Inclusion Criteria

Patients with radiologically FIGO stage IIIB/IIIC EOC based on the conventional
CT scan who are
• scheduled to undergo primary cytoreductive surgery and
a) in whom EOC is histologically proven, or
b) in whom EOC is cytologically suspected and a serum CA125/CEA ratio > 25 is
found
or
• treated with neoadjuvant chemotherapy (NACT) and are scheduled to undergo
interval cytoreductive surgery and
a) in whom EOC is histologically proven, or
b) in whom EOC is cytologically suspected and a serum CA125/CEA ratio > 25 was
found before NACT
c) and with radiologically FIGO stage IIIB/IIIC EOC based on the response
evaluation CT scan after NACT

Exclusion Criteria

1. Women younger than 30 years of age (in accordance with the guidelines of the
Netherlands Commission on Radiation Dosimetry, as the total radiation dose will
be 7.2 mSv)
2. Patients who previously underwent primary laparotomy and in whom complete or
optimal cytoreduction was not considered feasible.
3. Contraindication for PET (pregnancy, lactating or severe claustrophobia)
4. Thrombocytopenia (platelet count < 100 x 10^9/L) and/or INR > 2
5. Impaired renal function (defined as eGFR < 50 mL/1.73 m2)
6. Impaired liver function (ALT, AST or total bilirubin > 3x upper limit of
normal)
7. Clinically significant abnormalities on ECG and/or clinically laboratory
test
8. Inability to tolerate lying supine for the duration of a PET/CT examination
(~110 minutes)
9. Patients with concomitant malignancy (except basal cell carcinoma of the
skin) or any condition that in the opinion of the investigators could
potentially jeopardize the health status of the patient
10. Patients not able to comply with the study procedures
11. Patients who did not give informed consent

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials